Segall Bryant & Hamill LLC Makes New $881,000 Investment in VanEck Biotech ETF $BBH

Segall Bryant & Hamill LLC bought a new position in VanEck Biotech ETF (NASDAQ:BBH) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,590 shares of the company’s stock, valued at approximately $881,000. Segall Bryant & Hamill LLC owned about 0.24% of VanEck Biotech ETF at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BBH. Northwestern Mutual Wealth Management Co. grew its stake in shares of VanEck Biotech ETF by 40,463.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock worth $93,506,000 after buying an additional 492,843 shares during the last quarter. Raymond James Financial Inc. lifted its stake in shares of VanEck Biotech ETF by 2.8% in the 3rd quarter. Raymond James Financial Inc. now owns 69,809 shares of the company’s stock valued at $11,566,000 after acquiring an additional 1,869 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of VanEck Biotech ETF by 44.3% in the 1st quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock valued at $12,473,000 after acquiring an additional 20,375 shares during the last quarter. Ascent Advisors LLC acquired a new stake in shares of VanEck Biotech ETF during the 1st quarter valued at $11,178,000. Finally, LPL Financial LLC boosted its holdings in shares of VanEck Biotech ETF by 63.5% during the 4th quarter. LPL Financial LLC now owns 31,813 shares of the company’s stock valued at $6,021,000 after acquiring an additional 12,351 shares in the last quarter. Institutional investors own 32.05% of the company’s stock.

Insider Activity at VanEck Biotech ETF

In other news, major shareholder Sardar Biglari sold 2,749 shares of the business’s stock in a transaction dated Thursday, July 16th. The stock was sold at an average price of $16.70, for a total transaction of $45,908.30. Following the sale, the insider directly owned 3,549,961 shares in the company, valued at approximately $59,284,348.70. The trade was a 0.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 10,493 shares of company stock worth $175,335 over the last quarter.

VanEck Biotech ETF Stock Performance

Shares of BBH stock opened at $210.38 on Thursday. VanEck Biotech ETF has a twelve month low of $156.45 and a twelve month high of $212.54. The stock’s fifty day simple moving average is $198.68 and its 200 day simple moving average is $193.21.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.